- Home
- BIAF vs EVGN Comparison
BIAF vs EVGN Comparison
Compare BIAF & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- EVGN
- Stock Information
- Founded
- BIAF 2014
- EVGN 1999
- Country
- BIAF United States
- EVGN Israel
- Employees
- BIAF N/A
- EVGN N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVGN Agricultural Chemicals
- Sector
- BIAF Health Care
- EVGN Industrials
- Exchange
- BIAF Nasdaq
- EVGN Nasdaq
- Market Cap
- BIAF 13.0M
- EVGN 10.9M
- IPO Year
- BIAF 2022
- EVGN N/A
- Fundamental
- Price
- BIAF $2.49
- EVGN $1.31
- Analyst Decision
- BIAF Hold
- EVGN Strong Buy
- Analyst Count
- BIAF 1
- EVGN 1
- Target Price
- BIAF N/A
- EVGN $3.50
- AVG Volume (30 Days)
- BIAF 3.3M
- EVGN 150.4K
- Earning Date
- BIAF 11-13-2025
- EVGN 11-20-2025
- Dividend Yield
- BIAF N/A
- EVGN N/A
- EPS Growth
- BIAF N/A
- EVGN N/A
- EPS
- BIAF N/A
- EVGN N/A
- Revenue
- BIAF $7,681,059.00
- EVGN $9,444,000.00
- Revenue This Year
- BIAF N/A
- EVGN N/A
- Revenue Next Year
- BIAF $20.04
- EVGN $12.35
- P/E Ratio
- BIAF N/A
- EVGN N/A
- Revenue Growth
- BIAF 4.99
- EVGN 42.25
- 52 Week Low
- BIAF $2.34
- EVGN $0.95
- 52 Week High
- BIAF $46.53
- EVGN $2.87
- Technical
- Relative Strength Index (RSI)
- BIAF 46.54
- EVGN 54.40
- Support Level
- BIAF $2.43
- EVGN $1.21
- Resistance Level
- BIAF $3.50
- EVGN $1.32
- Average True Range (ATR)
- BIAF 0.29
- EVGN 0.08
- MACD
- BIAF -0.09
- EVGN -0.00
- Stochastic Oscillator
- BIAF 5.69
- EVGN 36.03
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.